AIDS TREATMENT NEWS #234, November 3, 1995
A government study of 215 volunteers with AIDS-related
cognitive impairment found no proof that peptide T was
helpful for treating this condition.
The volunteers were randomly assigned to receive either
peptide T (intranasally, up to six mg/day) or placebo for six
months; for the next six months, everyone was given peptide
T, and they could continue the medication beyond one year if
they wanted. Cognitive impairment (which includes
difficulties with memory, attention, language, problem
solving, spatial ability, and visual-motor coordination) was
measured by standard neuropsychological tests. The treatment
group showed no statistically significant improvement
compared to the control group.
The study also found no toxicity from peptide T.
Recruiting for this study began in March 1991. It took a long
time to find volunteers -- probably because AIDS-related
cognitive impairment is less common than had been expected,
and because it can often be treated effectively with AZT.
This clinical trial was conducted by the U.S. National
Institute of Mental Health, with additional funding from the
U.S. National Institute of Allergy and Infectious Diseases